Blueprint Medicines (NASDAQ:BPMC) issued its earnings results on Thursday. The biotechnology company reported ($2.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.08) by ($0.20), MarketWatch Earnings reports. Blueprint Medicines had a negative net margin of 525.44% and a negative return on equity of 71.24%. The firm had revenue of $8.34 million during the quarter, compared to the consensus estimate of $7.56 million.
Blueprint Medicines stock opened at $73.18 on Friday. The stock has a 50-day moving average of $76.68 and a two-hundred day moving average of $67.22. The company has a current ratio of 7.17, a quick ratio of 7.14 and a debt-to-equity ratio of 0.13. Blueprint Medicines has a one year low of $43.29 and a one year high of $101.76.
In related news, Director Nicholas Lydon sold 26,007 shares of Blueprint Medicines stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $80.45, for a total transaction of $2,092,263.15. Following the transaction, the director now owns 48,340 shares in the company, valued at $3,888,953. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jeffrey W. Albers sold 20,000 shares of Blueprint Medicines stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $64.67, for a total value of $1,293,400.00. Following the transaction, the chief executive officer now owns 161,434 shares in the company, valued at approximately $10,439,936.78. The disclosure for this sale can be found here. Insiders sold 66,349 shares of company stock worth $5,001,908 over the last three months. Corporate insiders own 3.81% of the company’s stock.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Read More: Blockchain
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.